Your browser doesn't support javascript.
loading
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19
Lucija Klaric; Jack S Gisby; Artemis Papadaki; Marisa D Muckian; Erin Macdonald-Dunlop; Jing Hua Zhao; Alex Tokolyi; Elodie Persyn; Erola Pairo-Castineira; Andrew P Morris; Anette Kalnapenkis; Anne Richmond; Arianna Landini; Åsa K Hedman; Bram Prins; Daniela Zanetti; Eleanor Wheeler; Charles Kooperberg; Chen Yao; John R Petrie; Jingyuan Fu; Lasse Folkersen; Mark Walker; Martin Magnusson; Niclas Eriksson; Niklas Mattsson-Carlgren; Paul RHJ Timmers; Shih-Jen Hwang; Stefan Enroth; Stefan Gustafsson; Urmo Vosa; Yan Chen; Agneta Siegbahn; Alexander Reiner; Åsa Johansson; Barbara Thorand; Bruna Gigante; Caroline Hayward; Christian Herder; Christian Gieger; Claudia Langenberg; Daniel Levy; Daria V Zhernakova; J Gustav Smith; Harry Campbell; Johan Sundstrom; John Danesh; Karl Michaëlsson; Karsten Suhre; Lars Lind; Lars Wallentin; Leonid Padyukov; Mikael Landén; Nicholas J Wareham; Andreas Göteson; Oskar Hansson; Per Eriksson; Rona J Strawbridge; Themistocles L Assimes; Tõnu Esko; Ulf Gyllensten; J Kenneth Baillie; Dirk S Paul; Peter K Joshi; Adam S Butterworth; Anders Mälarstig; Nicola Pirastu; James F Wilson; James E Peters.
Afiliação
  • Lucija Klaric; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, United Kingdom
  • Jack S Gisby; Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom
  • Artemis Papadaki; Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, United Kingdom
  • Marisa D Muckian; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom
  • Erin Macdonald-Dunlop; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom
  • Jing Hua Zhao; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Alex Tokolyi; Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK
  • Elodie Persyn; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
  • Erola Pairo-Castineira; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
  • Andrew P Morris; Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, The University of Manchester, Manchester, UK
  • Anette Kalnapenkis; Institute of Genomics, University of Tartu, Tartu, Estonia
  • Anne Richmond; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, United Kingdom
  • Arianna Landini; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom
  • Åsa K Hedman; Department of Medicine, Karolinska Institute, Stockholm, Sweden
  • Bram Prins; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Daniela Zanetti; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
  • Eleanor Wheeler; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK
  • Charles Kooperberg; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Chen Yao; Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
  • John R Petrie; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK
  • Jingyuan Fu; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands
  • Lasse Folkersen; Danish National Genome Center, Copenhagen, Denmark.
  • Mark Walker; Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
  • Martin Magnusson; Department of Clinical Sciences, Lund University, Malmö, Sweden
  • Niclas Eriksson; Uppsala Clinical Research Center (UCR), Uppsala University, Uppsala, Sweden
  • Niklas Mattsson-Carlgren; Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden
  • Paul RHJ Timmers; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, United Kingdom
  • Shih-Jen Hwang; Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
  • Stefan Enroth; Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
  • Stefan Gustafsson; Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  • Urmo Vosa; Institute of Genomics, University of Tartu, Tartu, Estonia
  • Yan Chen; Department of Medicine Solna, Karolinska Institutet
  • Agneta Siegbahn; Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  • Alexander Reiner; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • Åsa Johansson; Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
  • Barbara Thorand; Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, München-Neuherberg, Germany
  • Bruna Gigante; Division of Cardiovascular Medicine, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
  • Caroline Hayward; MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, United Kingdom
  • Christian Herder; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany
  • Christian Gieger; Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, München-Neuherberg, Germany
  • Claudia Langenberg; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK
  • Daniel Levy; Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
  • Daria V Zhernakova; University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands
  • J Gustav Smith; Department of Cardiology, Clinical Sciences, Lund University and Skåne University Hospital, Lund, Sweden
  • Harry Campbell; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom
  • Johan Sundstrom; Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  • John Danesh; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Karl Michaëlsson; Department of Surgcial Sciences, Unit of Medical Epidemiology, Uppsala University, Uppsala, Sweden
  • Karsten Suhre; Department of Physiology and Biophysics, Weill Cornell Medicine-Qatar, Doha, Qatar
  • Lars Lind; Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  • Lars Wallentin; Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden
  • Leonid Padyukov; Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
  • Mikael Landén; Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
  • Nicholas J Wareham; MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge School of Clinical Medicine, Cambridge, UK
  • Andreas Göteson; Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden
  • Oskar Hansson; Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden
  • Per Eriksson; Division of Cardiovascular Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
  • Rona J Strawbridge; Institute of Health and Wellbeing, College of Medicine, Veterinary and Life Sciences, University of Glasgow, UK
  • Themistocles L Assimes; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
  • Tõnu Esko; Institute of Genomics, University of Tartu, Tartu, Estonia
  • Ulf Gyllensten; Department of Immunology, Genetics and Pathology, Uppsala University, Sweden
  • J Kenneth Baillie; Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK
  • Dirk S Paul; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
  • Peter K Joshi; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom
  • Adam S Butterworth; British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Anders Mälarstig; Karolinska Institute, Stockholm, Sweden
  • Nicola Pirastu; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom
  • James F Wilson; Centre for Global Health Research, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh, United Kingdom
  • James E Peters; Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21254789
ABSTRACT
Severe COVID-19 is characterised by immunopathology and epithelial injury. Proteomic studies have identified circulating proteins that are biomarkers of severe COVID-19, but cannot distinguish correlation from causation. To address this, we performed Mendelian randomisation (MR) to identify proteins that mediate severe COVID-19. Using protein quantitative trait loci (pQTL) data from the SCALLOP consortium, involving meta-analysis of up to 26,494 individuals, and COVID-19 genome-wide association data from the Host Genetics Initiative, we performed MR for 157 COVID-19 severity protein biomarkers. We identified significant MR results for five proteins FAS, TNFRSF10A, CCL2, EPHB4 and LGALS9. Further evaluation of these candidates using sensitivity analyses and colocalization testing provided strong evidence to implicate the apoptosis-associated cytokine receptor FAS as a causal mediator of severe COVID-19. This effect was specific to severe disease. Using RNA-seq data from 4,778 individuals, we demonstrate that the pQTL at the FAS locus results from genetically influenced alternate splicing causing skipping of exon 6. We show that the risk allele for very severe COVID-19 increases the proportion of transcripts lacking exon 6, and thereby increases soluble FAS. Soluble FAS acts as a decoy receptor for FAS-ligand, inhibiting apoptosis induced through membrane-bound FAS. In summary, we demonstrate a novel genetic mechanism that contributes to risk of severe of COVID-19, highlighting a pathway that may be a promising therapeutic target.
Licença
cc_by_nd
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo prognóstico / Review Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Experimental_studies / Estudo prognóstico / Review Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
...